Product Profiles

Article

Femtosecond platform

Femtosecond platform

The systems operate at pulse frequencies in the megahertz range and use very low pulse energy. This enables excellent visual outcomes and faster recovery.

For further information please visit http://www.femtoldv.com/

25G cannula

The cannula has a short bevel, meaning it can fully enter the needle tip into the tumour. The diagnostic yield is higher due to the superior cellularity of the biopsy.

For more information please contact info@geuder.de

HD-OCT platform

The Cirrus HD-OCT features a retina application that provides Advanced Retinal Pigment Epithelium (RPE) analysis, This mean the clinicians can objectively monitor changes in dry AMD.

RPE elevation, area and volume can also be tracked with the application and can identify and measure the area of transparent regions in the RPE.

Please visit http://www.meditec.zeiss.com/cirrus/ for more information

Presbyopia treatment system

The system uses bi-aspheric multifocal ablation profiles, enabling an optimum relationship between near and distance vision. It works by directing the dominant eye on distance vision and directs the nondominant eye towards near vision.

Rapid visual recovery is possible at all visual distances with the PresbyMAX and is welltolerated in uncorrected conditions. The system is ideal for patients who would like excellent distance vision. Ocular defects such as myopia, hyperopia and astigmatism can be corrected with the PresbyMAX.

For further details please visit http://www.eye-tech-solutions.com/

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.